Onychomycosis: Improved Cure Rates with Itraconazole and Terbinafine
| Autor: | W H Replogle, Deborah S. King, T K Harrell, Sara L. Noble, W W Necomb |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Antifungal
medicine.medical_specialty Antifungal Agents Itraconazole business.industry medicine.drug_class Pulse therapy Public Health Environmental and Occupational Health Naphthalenes Drug interaction Placebo Dermatology Drug Costs Tolerability Consumer Product Safety Onychomycosis medicine Humans Terbinafine Drug Interactions Family Practice business medicine.drug |
| Zdroj: | The Journal of the American Board of Family Medicine. 13:268-273 |
| ISSN: | 1558-7118 1557-2625 |
| DOI: | 10.3122/15572625-13-4-268 |
| Popis: | Onychomycosis is a disease that is important to our patients. Based on the current literature, recent developments of newer antifungal agents have improved cure rates of onychomycosis in the past few years (Table 3). No significant differences in safety and tolerability between itraconazole and terbinafine exist. Terbinafine does appear to have a preferable drug interaction profile. Daily therapy with either agent at standard doses has been shown to be effective when compared with placebo. When studies have directly compared daily administration of terbinafine and itraconazole, both medications have shown similar efficacy. Daily terbinafine therapy, however, appears to be more effective than pulse therapy with itraconazole. In addition, one small study showed a trend in favor of continuous rather than intermittent terbinafine therapy and similar efficacy of intermittent itraconazole and intermittent terbinafine therapy. Furthermore, terbinafine is more cost-effective than itraconazole. Finally, as quality-of-life data suggest, onychomycosis is important to our patients and affects both physical and psychosocial components of our patients' lives. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|